Explore the recent success of Samsung Biologics as they secure a massive contract worth 1.7 trillion won. With cumulative orders surpassing 4 trillion won this year, we analyze the implications of their current PER and future prospects. Join us in cheering for their growth!

---

(p1) Lets take a look at Samsung Biologics.
(p2) Today, there was some good news. Samsung Biologics announced a contract worth 1.7 trillion won! This year, the cumulative orders have already surpassed 4 trillion won. Its positive that the orders are continuously increasing every year.
(p3) We cant overlook the PER, right? Here is the trend of PER since the IPO.
(p4) The PER is at a level of 73, but immediately after the IPO, it reached a staggering 600. CMO is fundamentally a productionfocused business. Its not a market pioneer like Tesla or Apple.
(p5) The meaning of a PER of 73 conceptually means that it should maintain a good atmosphere like this for 73 years. Fortunately, the quarterly net profit is steadily increasing.
(p6) For this value to be justified, orders must surge, or profit margins must be maintained at a high level, which is not an easy task.
(p7) Still, Ill be cheering for Samsung Biologics and watching closely. Lets hope it becomes the TSMC of the CMO world. Thank you.
Youtube Link - Issue Tracker